Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus

Abstract

Despite pharmacotherapeutic advancements in the management of type 1 diabetes mellitus during the past several decades, patients struggle to achieve glycemic goals. Additionally, hypoglycemia, especially in extremes of age, decreases quality of life. The lack of optimal glycemic control and risk for hypoglycemia are multifactorial. Nevertheless, endeavors aiming to develop pharmacotherapeutic options with enhanced pharmacokinetic, pharmacodynamic, and clinical profiles continue. This review article discusses recent ventures in 3 categories of insulin, non-insulin, and glucagon products.

Diabetic‑induced alterations in hepatic glucose and lipid metabolism: The role of type 1 and type 2 diabetes mellitus (Review)

“…However, the underlying mechanism by which metformin inhibits hepatic gluconeogenesis remains unknown. The addition of metformin to insulin therapy in T1DM is still under debate and previous findings of metformin in patients with T1DM have resulted in conflicting results (71).…”